Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Income from Continuing Operations (2022 - 2025)

Stoke Therapeutics has reported Income from Continuing Operations over the past 4 years, most recently at 57824000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 441.27% year-over-year to 57824000.0; the TTM value through Dec 2025 reached 6775000.0, up 92.4%, while the annual FY2025 figure was 6834000.0, 92.3% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 57824000.0 at Stoke Therapeutics, down from 38347000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 112879000.0 in Q1 2025 and troughed at 57824000.0 in Q4 2025.
  • A 4-year average of 18878500.0 and a median of 25696000.0 in 2022 define the central range for Income from Continuing Operations.
  • On a YoY basis, Income from Continuing Operations climbed as much as 527.99% in 2025 and fell as far as 441.27% in 2025.
  • Year by year, Income from Continuing Operations stood at 25697000.0 in 2022, then fell by 5.07% to 26999000.0 in 2023, then skyrocketed by 60.43% to 10683000.0 in 2024, then plummeted by 441.27% to 57824000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for STOK at 57824000.0 in Q4 2025, 38347000.0 in Q3 2025, and 23483000.0 in Q2 2025.